“We made significant progress at the end of last year and hope to continue that pace in 2025,” said James Rolke, Chief Executive Officer of Revelation. “Now that the Phase 1b PRIME clinical study is up and running we anticipate the completion of enrollment and more importantly topline data mid-year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REVB:
- Revelation doses first patient in PRIME Phase 1b clinical study
- Revelation Biosciences receives continued Nasdaq listing approval
- Revelation Biosciences Inc trading halted, news pending
- Upcoming Stock Splits This Week (January 27 to January 31) – Stay Invested
- Revelation Biosciences announces 1-for-16 reverse stock split